Get started
Author

U Gill

Observed names: U S Gill, U. Gill, U. S. Gill, U.S. Gill
OpenAlex ID: A5114063791
713 Factors Determining Bone Mineral Density Loss in Chronic Hepatitis B Patients: Is Tenofovir Disoproxil Fumarate the Main Culprit?
2011 · U.S. Gill, S. Al-Shamma, et al. · Journal of Hepatology · 7
Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit?
2011 · U S Gill, S Al-Shamma, et al. · Gut · 6
PDF
Transcriptome profiles of NK and T cells associated with immune control in chronic hepatitis B patients treated with pegylated interferon alpha-nucleos(t)ide analogue sequential therapy
2017 · U.S. Gill, N.L. Bert, et al. · Journal of Hepatology · 1
An Immunological Biomarker to Predict Hepatic Flares upon Nuc Therapy Discontinuation in Chronic Hepatitis B
2016 · L. Rivino, N. Le Bert, et al. · Journal of Hepatology · 1
OC48 HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential
2025 · S D’Anna, L Piermatteo, et al. · Sexually Transmitted Infections
SC-5 HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir
2024 · S D’Anna, L Piermatteo, et al. · Sexually Transmitted Infections
PDF
Gene Ontology Enrichment and Ingenuity Pathway Analysis Reveals Differentially Immune Regulated Networks in Treated Compared to Untreated Chronic Hepatitis B Patients.
2019 · U Gill, Nina Le Bert, et al. · Hepatology
Exhaustion of virus-specific and total B cellpopulations by HBV infection
2018 · L. Salimzadeh, N. Le Bert, et al. · Journal of Hepatology
Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes
2018 · U.S. Gill, L.J. Pallett, et al. · Journal of Hepatology
Pro-fibrogenic mediator osteopontin is intimately involved in chronic hepatitis B and promotes cccDNA production
2018 · S. Phillips, J. Coombes, et al. · Journal of Hepatology
Peripheral and intrahepatic virological phenotyping in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the “grey-zone” viral load cohort: Can grey-zone patients be candidate to treatment?
2017 · R. Salpini, L. Colagrossi, et al. · Digestive and Liver Disease
PD-1+ CD8+ T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B
2017 · N. Le Bert, L. Rivino, et al. · Journal of Hepatology
In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?
2017 · R. Salpini, A. Battisti, et al. · Journal of Hepatology
Modifications of virus-specific and total B cell populations by hepatitis B virus infection
2017 · L. Salimzadeh, N.L. Bert, et al. · Journal of Hepatology
Peripheral and intrahepatic virological phenotyping in eAg negative chronic hepatitis B to evaluate risk of disease progression and hepatocellular carcinoma in the “grey-zone” viral load cohort
2017 · V. Svicher, R. Salpini, et al. · Journal of Hepatology
NK cell function is restored with sequential NUC therapy and correlates with treatment response in Chronic Hepatitis B
2015 · U Gill, Dimitra Peppa, et al. · Hepatology
P152 Sequential Nuc Therapy Following Pegylated Interferon-alpha Exposure Restores Innate Immune Responses Conferring a Treatment Advantage Over Nuc Monotherapy in Chronic Hepatitis B
2014 · U.S. Gill, D. Peppa, et al. · Journal of Hepatology
O106 Clonal Hepatocyte Repopulation in the Young Adult Hbv Infected Liver Challenges the Concept of a Generic Immune Tolerant Disease Phase
2014 · P.T.F. Kennedy, U.S. Gill, et al. · Journal of Hepatology
PWE-144 Frax Score in the Assessment of Bone Mineral Density Changes in Tenofovir Treated Chronic Hepatitis B Patients
2013 · U S Gill, A Zissimopoulos, et al. · Gut
PDF
746 Induction Maintenance Therapy in Chronic Hepatitis B; Step-down From Combination Lamivudine and Tenofovir to Lamivudine Monotherapy – a Potential New Treatment Strategy
2013 · U.S. Gill, L. Payaniandy, et al. · Journal of Hepatology
PDF
325 Probing Hepatic Antigen Presentation in Patients With Chronic Hbv Infection
2013 · A. Chen, A. Schurich, et al. · Journal of Hepatology
PDF
PMO-176 Induction maintenance treatment in chronic hepatitis B; step-down from tenofovir and lamivudine to lamivudine monotherapy is effective
2012 · U S Gill, L Payaniandy, et al. · Gut
PDF
PMO-148 Evaluation of liver fibrosis in young adult patients with chronic hepatitis B virus
2012 · C Patel, U S Gill, et al. · Gut
PDF
PMO-175 Can a 3-month “stopping rule” for pegylated-interferon-α be applied to a UK population of chronic hepatitis B infected patients of mixed genotype?
2012 · U S Gill, L Payaniandy, et al. · Gut
PDF
441 Maximal Boosting of Innate Immunity During Pegylated Interferon-aplha Therapy Is Reached at 48 Weeks in E-antigen Positive Chronic Hepatitis B
2012 · U.S. Gill, M. Papadaki, et al. · Journal of Hepatology
Works count: 29
Citation count: 15
H-index: 2
I10-index:
Year
Topic
Type